We also demonstrate for the first time that treatment with the monoclonal antibody alirocumab significantly reduces hepatic PCSK9 expression and subsequently increases LDL-R expression in the liver, which is accompanied by attenuation of alcohol-induced liver steatosis, inflammation, oxidative stress, and hepatocellular injury. This evidence concerns the gene PCSK9 and fatty liver disease.